Fibroblast growth factor receptor 2

"Are You Dense?" Foundation Launches National Recognition for Clinical Advancements in Dense Breast Imaging

Retrieved on: 
Friday, September 15, 2023

Foundation presented the first in a series of Cancer Research & Innovations awards to diagnostic imaging specialist Dr. Robert Bard (NYC).

Key Points: 
  • Foundation presented the first in a series of Cancer Research & Innovations awards to diagnostic imaging specialist Dr. Robert Bard (NYC).
  • At the time, no regulatory standard enforced the need for this 2nd scan, attributing to many undetected breast cancer tumors concealed by dense breast tissue.
  • Since 2019, Mr. Cappello's Are You Dense Advocacy Foundation succeeded in helping to pass National legislation to federally mandate breast screening centers to address the dense breast crisis with the ultrasound complement.
  • In 2014, Imaging Technology News (ITN) introduced breast cancer survivor-turned-crusader Dr. Nancy Cappello and her story about having dense breast tissue leading to a late-stage cancer.

Trefoil Therapeutics’ Lead Investigational Candidate TTHX1114 Improves Rate of Visual Recovery after Descemet Stripping Only (DSO) in Phase 2 STORM Data Presented at ASCRS Annual Meeting

Retrieved on: 
Monday, May 8, 2023

A separate STORM analysis assessed visual morbidity in patients with Fuchs endothelial corneal dystrophy (FECD) prior to surgery using the V-Fuchs Questionnaire (V-FUCHS).

Key Points: 
  • A separate STORM analysis assessed visual morbidity in patients with Fuchs endothelial corneal dystrophy (FECD) prior to surgery using the V-Fuchs Questionnaire (V-FUCHS).
  • The data were presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in San Diego.
  • The study results showed TTHX1114 improved best-corrected visual acuity (BCVA) and central corneal thickness (CCT) after DSO in the 49 subjects/64 eyes.
  • Faster recovery was associated with smaller descemetorhexis (surgical removal of Descemet membrane), while comorbid diabetes appeared to delay recovery.

Rare Disease PTEN Hamartoma Tumour Syndrome (PHTS) Granted International Classification of Diseases (ICD) Code

Retrieved on: 
Saturday, October 1, 2022

PTEN Research Foundation, a charity which funds and facilitates research with the aim of developing new and better treatments for PTEN Hamartoma Tumour Syndrome (PHTS), today announced that the rare genetic disease, PHTS, has been given a new and unique disease code in the International Classification of Diseases revision 10, Clinical Modification (ICD-10-CM) system that is managed by the US Center for Disease Control and Prevention (CDC).

Key Points: 
  • PTEN Research Foundation, a charity which funds and facilitates research with the aim of developing new and better treatments for PTEN Hamartoma Tumour Syndrome (PHTS), today announced that the rare genetic disease, PHTS, has been given a new and unique disease code in the International Classification of Diseases revision 10, Clinical Modification (ICD-10-CM) system that is managed by the US Center for Disease Control and Prevention (CDC).
  • For example, a person experiencing migraine headaches will receive a code from category G43 and a person with a urinary tract infection will receive an N39.0 code.
  • These codes are used routinely for health insurance billing and reimbursement, and also support clinical, natural history and epidemiological research.
  • PHTS is a disease caused by an alteration in the PTEN gene.

Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress

Retrieved on: 
Monday, September 5, 2022

"We believe the preclinical results being presented at the ESMO Congress showcase the enhanced anti-tumor activity and selectivity of TYRA-300 as compared to other agents in the class," said Todd Harris, CEO of TYRA.

Key Points: 
  • "We believe the preclinical results being presented at the ESMO Congress showcase the enhanced anti-tumor activity and selectivity of TYRA-300 as compared to other agents in the class," said Todd Harris, CEO of TYRA.
  • Details of the poster presentation are as follows:
    Regular abstracts will be published on the ESMO website on September 5, 2022.
  • The poster presentation on TYRA-300 will be made available on the TYRA website under the "For Investors" section on September 12, 2022.
  • TYRA cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

Cogent Biosciences to Host Virtual R&D Investor Event

Retrieved on: 
Tuesday, March 29, 2022

CAMBRIDGE, Mass.andBOULDER, Colo., March 29, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announceddetails for its planned Virtual R&D Investor Event on Friday, April 8, 2022, beginning at 4:05 PM EDT.

Key Points: 
  • CAMBRIDGE, Mass.andBOULDER, Colo., March 29, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announceddetails for its planned Virtual R&D Investor Event on Friday, April 8, 2022, beginning at 4:05 PM EDT.
  • The Virtual Investor R&D Event will coincide with the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, at which Cogent will share data from two poster presentations.
  • Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases.
  • Cogent Biosciences is based inCambridge, MAandBoulder, CO.Visit our website for more information at www.cogentbio.com .Follow Cogent Biosciences on social media: Twitter and LinkedIn .

Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference

Retrieved on: 
Tuesday, February 22, 2022

CARLSBAD, Calif., Feb. 22, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that TYRA management will be participating in a corporate panel discussion at the Cowen 42nd Annual Healthcare Conference, taking place virtually March 7-9, 2022.

Key Points: 
  • CARLSBAD, Calif., Feb. 22, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that TYRA management will be participating in a corporate panel discussion at the Cowen 42nd Annual Healthcare Conference, taking place virtually March 7-9, 2022.
  • Details are below:
    A live webcast of the panel will be available on the Company's website at https://tyra.bio in the " For Investors " section.
  • Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer.
  • TYRA is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers.

BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

Retrieved on: 
Tuesday, June 1, 2021

The approval of TRUSELTIQ provides a new and exciting treatment option for patients with CCA harboring an FGFR2 fusion, said Stacie Lindsey, Chief Executive Officer of the Cholangiocarcinoma Foundation.

Key Points: 
  • The approval of TRUSELTIQ provides a new and exciting treatment option for patients with CCA harboring an FGFR2 fusion, said Stacie Lindsey, Chief Executive Officer of the Cholangiocarcinoma Foundation.
  • BridgeBio and Helsinn Groups affiliate, Helsinn Therapeutics (U.S.), Inc., will be jointly responsible for commercialization activities in the U.S. and will share U.S. profits and losses on an equal basis.
  • Helsinn Group will have exclusive commercialization rights on infigratinib outside of the U.S., excluding China, Hong Kong and Macau.
  • Moreover, BridgeBio and QED operate in a very competitive environment in which new risks emerge from time to time.

BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

Retrieved on: 
Friday, May 28, 2021

The approval of TRUSELTIQ provides a new and exciting treatment option for patients with CCA harboring an FGFR2 fusion, said Stacie Lindsey, Chief Executive Officer of the Cholangiocarcinoma Foundation.

Key Points: 
  • The approval of TRUSELTIQ provides a new and exciting treatment option for patients with CCA harboring an FGFR2 fusion, said Stacie Lindsey, Chief Executive Officer of the Cholangiocarcinoma Foundation.
  • BridgeBio and Helsinn Groups affiliate, Helsinn Therapeutics (U.S.), Inc., will be jointly responsible for commercialization activities in the U.S. and will share U.S. profits and losses on an equal basis.
  • Helsinn Group will have exclusive commercialization rights on infigratinib outside of the U.S., excluding China, Hong Kong and Macau.
  • Moreover, BridgeBio and QED operate in a very competitive environment in which new risks emerge from time to time.

Incyte Announces the European Commission Approval of Pemazyre® (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement

Retrieved on: 
Monday, March 29, 2021

Pemazyre offers a much-needed option to eligible patients that have only had few effective treatment options until today.

Key Points: 
  • Pemazyre offers a much-needed option to eligible patients that have only had few effective treatment options until today.
  • Historically, patients living with advanced cholangiocarcinoma have had very limited treatment options, said Helen Morement, CEO, AMMF The Cholangiocarcinoma Charity.
  • FIGHT-302 is a Phase 3 study investigating Pemazyre as a first-line treatment for patients with cholangiocarcinoma with FGFR2 fusions or rearrangements.
  • In Europe, Pemazyre is approved for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Basilea reports positive interim results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene mutation- or amplification-positive patients with bile duct cancer (iCCA)

Retrieved on: 
Wednesday, March 24, 2021

The interim analysis of cohort 2 is based on 14 evaluable patients who had at least one post-baseline tumor assessment.

Key Points: 
  • The interim analysis of cohort 2 is based on 14 evaluable patients who had at least one post-baseline tumor assessment.
  • The positive interim analysis allows the study to advance to its next stage and enrol a total of 43 patients.
  • Dr. Marc Engelhardt, Chief Medical Officer, said: We are very pleased with the positive interim results for this cohort of iCCA patients with FGFR2 gene mutations or amplifications.
  • The clinical benefit with derazantinib is similar to that reported for iCCA patients with FGFR2 gene fusions earlier this year.